Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

• Status: Completed
• Trial end date: 2010-04-27
• Target enrollment: 0
• Participant gender: All

Summary

The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
• Treatments: Lurasidone Hydrochloride; Risperidone

Criteria

Main Inclusion Criteria:

• Patient meets DSM-IV criteria for schizophrenia.

• Patient is 18 or older but younger than 75 years of age on the day of signing informed consent.

• Patient understands the objectives, nature, and other aspects of the study and voluntarily agrees to participate in the study by providing written informed consent.

Main Exclusion Criteria:

• Patient has a history of neuroleptic malignant syndrome, water intoxication, or paralytic ileus.

• Patient has Parkinson's disease.

• Patient has a history or complication of malignancy.